Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients

Meta-analysis of clinical trials

O. Fabrizi, Vivek Dixit, Piergiorgio Messa, Paul Martin

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The efficacy and safety of pegylated interferon monotherapy in patients with chronic renal failure and chronic hepatitis C remains unclear, although a number of small clinical trials have been published addressing this issue. A systematic review of the literature with a meta-analysis of clinical trials was performed in order to assess efficacy and safety of initial pegylated interferon monotherapy in chronic renal failure patients with chronic hepatitis C. The primary outcome was sustained virological response (as a measure of efficacy); the secondary outcome was drop-out rate (as a measure of tolerability). The random effects model of Der Simonian and Laird was used, with heterogeneity and sensitivity analyses. Sixteen clinical trials (254 unique patients) were identified, five (31%) being controlled studies; the majority (15/16=94%) regarded patients on long-term dialysis. The summary estimate for sustained virological response and drop-out rate was 33% [95% Confidence Intervals (95%CI) 24-43] and 23% (95%CI, 14-33), respectively. The most frequent side-effects requiring interruption of treatment were haematological (18%) and gastrointestinal (14%). In the group of controlled clinical trials, thesummaryestimate for sustained viral response and drop-out rate was 38% (95% CI, 18-59), and 15% (95% CI, 3-26), respectively. The studies were heterogeneous with regard to sustained virological response and drop-out rate. Pegylated IFN does not provide an added benefit in terms of virological response in comparison with standard IFN monotherapy. Tolerance to pegylated-IFN monotherapy was unsatisfactory. Prospective trials are in progress to assess the optimal antiviral therapy for chronic hepatitis C in dialysis patients.

Original languageEnglish
Pages (from-to)768-775
Number of pages8
JournalJournal of Medical Virology
Volume82
Issue number5
DOIs
StatePublished - May 1 2010

Fingerprint

Chronic Hepatitis C
Interferons
Meta-Analysis
Dialysis
Clinical Trials
Chronic Kidney Failure
Confidence Intervals
Safety
Controlled Clinical Trials
Antiviral Agents
Therapeutics

Keywords

  • Dialysis
  • Drop-out
  • Hepatitis C
  • Pegylated interferon
  • Virological response

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients : Meta-analysis of clinical trials. / Fabrizi, O.; Dixit, Vivek; Messa, Piergiorgio; Martin, Paul.

In: Journal of Medical Virology, Vol. 82, No. 5, 01.05.2010, p. 768-775.

Research output: Contribution to journalArticle

@article{44e67f9f85b24b78a234b310e8f72505,
title = "Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: Meta-analysis of clinical trials",
abstract = "The efficacy and safety of pegylated interferon monotherapy in patients with chronic renal failure and chronic hepatitis C remains unclear, although a number of small clinical trials have been published addressing this issue. A systematic review of the literature with a meta-analysis of clinical trials was performed in order to assess efficacy and safety of initial pegylated interferon monotherapy in chronic renal failure patients with chronic hepatitis C. The primary outcome was sustained virological response (as a measure of efficacy); the secondary outcome was drop-out rate (as a measure of tolerability). The random effects model of Der Simonian and Laird was used, with heterogeneity and sensitivity analyses. Sixteen clinical trials (254 unique patients) were identified, five (31{\%}) being controlled studies; the majority (15/16=94{\%}) regarded patients on long-term dialysis. The summary estimate for sustained virological response and drop-out rate was 33{\%} [95{\%} Confidence Intervals (95{\%}CI) 24-43] and 23{\%} (95{\%}CI, 14-33), respectively. The most frequent side-effects requiring interruption of treatment were haematological (18{\%}) and gastrointestinal (14{\%}). In the group of controlled clinical trials, thesummaryestimate for sustained viral response and drop-out rate was 38{\%} (95{\%} CI, 18-59), and 15{\%} (95{\%} CI, 3-26), respectively. The studies were heterogeneous with regard to sustained virological response and drop-out rate. Pegylated IFN does not provide an added benefit in terms of virological response in comparison with standard IFN monotherapy. Tolerance to pegylated-IFN monotherapy was unsatisfactory. Prospective trials are in progress to assess the optimal antiviral therapy for chronic hepatitis C in dialysis patients.",
keywords = "Dialysis, Drop-out, Hepatitis C, Pegylated interferon, Virological response",
author = "O. Fabrizi and Vivek Dixit and Piergiorgio Messa and Paul Martin",
year = "2010",
month = "5",
day = "1",
doi = "10.1002/jmv.21542",
language = "English",
volume = "82",
pages = "768--775",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients

T2 - Meta-analysis of clinical trials

AU - Fabrizi, O.

AU - Dixit, Vivek

AU - Messa, Piergiorgio

AU - Martin, Paul

PY - 2010/5/1

Y1 - 2010/5/1

N2 - The efficacy and safety of pegylated interferon monotherapy in patients with chronic renal failure and chronic hepatitis C remains unclear, although a number of small clinical trials have been published addressing this issue. A systematic review of the literature with a meta-analysis of clinical trials was performed in order to assess efficacy and safety of initial pegylated interferon monotherapy in chronic renal failure patients with chronic hepatitis C. The primary outcome was sustained virological response (as a measure of efficacy); the secondary outcome was drop-out rate (as a measure of tolerability). The random effects model of Der Simonian and Laird was used, with heterogeneity and sensitivity analyses. Sixteen clinical trials (254 unique patients) were identified, five (31%) being controlled studies; the majority (15/16=94%) regarded patients on long-term dialysis. The summary estimate for sustained virological response and drop-out rate was 33% [95% Confidence Intervals (95%CI) 24-43] and 23% (95%CI, 14-33), respectively. The most frequent side-effects requiring interruption of treatment were haematological (18%) and gastrointestinal (14%). In the group of controlled clinical trials, thesummaryestimate for sustained viral response and drop-out rate was 38% (95% CI, 18-59), and 15% (95% CI, 3-26), respectively. The studies were heterogeneous with regard to sustained virological response and drop-out rate. Pegylated IFN does not provide an added benefit in terms of virological response in comparison with standard IFN monotherapy. Tolerance to pegylated-IFN monotherapy was unsatisfactory. Prospective trials are in progress to assess the optimal antiviral therapy for chronic hepatitis C in dialysis patients.

AB - The efficacy and safety of pegylated interferon monotherapy in patients with chronic renal failure and chronic hepatitis C remains unclear, although a number of small clinical trials have been published addressing this issue. A systematic review of the literature with a meta-analysis of clinical trials was performed in order to assess efficacy and safety of initial pegylated interferon monotherapy in chronic renal failure patients with chronic hepatitis C. The primary outcome was sustained virological response (as a measure of efficacy); the secondary outcome was drop-out rate (as a measure of tolerability). The random effects model of Der Simonian and Laird was used, with heterogeneity and sensitivity analyses. Sixteen clinical trials (254 unique patients) were identified, five (31%) being controlled studies; the majority (15/16=94%) regarded patients on long-term dialysis. The summary estimate for sustained virological response and drop-out rate was 33% [95% Confidence Intervals (95%CI) 24-43] and 23% (95%CI, 14-33), respectively. The most frequent side-effects requiring interruption of treatment were haematological (18%) and gastrointestinal (14%). In the group of controlled clinical trials, thesummaryestimate for sustained viral response and drop-out rate was 38% (95% CI, 18-59), and 15% (95% CI, 3-26), respectively. The studies were heterogeneous with regard to sustained virological response and drop-out rate. Pegylated IFN does not provide an added benefit in terms of virological response in comparison with standard IFN monotherapy. Tolerance to pegylated-IFN monotherapy was unsatisfactory. Prospective trials are in progress to assess the optimal antiviral therapy for chronic hepatitis C in dialysis patients.

KW - Dialysis

KW - Drop-out

KW - Hepatitis C

KW - Pegylated interferon

KW - Virological response

UR - http://www.scopus.com/inward/record.url?scp=77950973727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950973727&partnerID=8YFLogxK

U2 - 10.1002/jmv.21542

DO - 10.1002/jmv.21542

M3 - Article

VL - 82

SP - 768

EP - 775

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 5

ER -